Wegovy price 2027 comes down to one date. If you pay cash for injectable Wegovy through Novo Nordisk's NovoCare (novocare.com) Pharmacy, new patients currently pay $199 a month for the 0.25 mg and 0.5 mg starter doses, an offer for two monthly fills that runs through December 31, 2026. After that the pen costs $349 a month for 0.25 mg to 2.4 mg and $399 for Wegovy HD 7.2 mg. The Wegovy pill is priced separately, by dose, from $149 a month. For people who pay out of pocket and are considering the injection, the next two months matter (prices checked on NovoCare on 26 October 2026).
By Alexandru Vieru | Independently researched | Updated October 2026. Every price below was read on Novo Nordisk's own NovoCare (novocare.com) pages on 26 October 2026. NovoCare program terms are set by Novo Nordisk and can change; verify current pricing at novocare.com before making decisions.
Bottom line: If you are planning to start injectable Wegovy on the NovoCare cash program, starting before December 31, 2026 gets you the $199 new-patient price for your first two fills of the starter doses. Every other fill, for every patient, is already at the standard price: $349 a month ($399 for Wegovy HD). Compounded semaglutide from licensed telehealth clinics remains a separate option. Cheaper at similar doses, but not FDA-approved. We break down both paths below.
What Is the NovoCare Program and Who Is It For?
NovoCare is Novo Nordisk's cash-pay assistance program for patients who do not have insurance coverage for Wegovy. The program is not a coupon or discount card. It is a direct sales channel where Novo Nordisk sets its own prices independent of insurance negotiations.
Who typically uses NovoCare:
- Self-pay patients without insurance, or with insurance that excludes GLP-1 weight-loss medications
- Patients whose insurance covers Ozempic for diabetes but not Wegovy for weight loss (different indication)
- People who have aged out of an employer plan and are between insurance options
- Patients who prefer not to go through prior authorization processes
NovoCare is distinct from the Medicare GLP-1 Bridge Program, which launched July 1, 2026, and covers brand-name Wegovy at $50 per month for eligible Medicare Part D enrollees. If you are on Medicare with Part D coverage, that Bridge Program is almost certainly the better option. See our Medicare GLP-1 Coverage 2026 guide for the mechanics.
If you are not on Medicare and are paying cash for brand-name Wegovy, NovoCare is the primary pricing mechanism you interact with.
Wegovy Price 2027: What Changes on December 31
NovoCare does not charge one flat rate for injectable Wegovy. Its own terms read: patients new to the Wegovy Savings offer or NovoCare Pharmacy pay $199 for each month of 0.25 mg and 0.5 mg, an offer for 2 monthly fills through December 31, 2026, then $349 per month for 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 2.4 mg and $399 per month for Wegovy HD 7.2 mg. One month is one box of 4 pens.
NovoCare self-pay pricing for the Wegovy pen (checked 26 October 2026):
| Dose | Monthly cost (NovoCare) |
|---|---|
| 0.25 mg and 0.5 mg, first two fills, new patients, through December 31, 2026 | $199/month |
| 0.25 mg to 2.4 mg, every other fill | $349/month |
| Wegovy HD 7.2 mg | $399/month |
The practical effect: the only thing that ends on December 31, 2026 is the two-fill new-patient offer. A patient who starts after that date pays $349 from the first fill. A patient already past the first two fills pays $349 now, so nothing changes for them on that date.
⚠️ Verify before acting. Novo Nordisk says it can modify or cancel the program at any time. Check your dose's price at novocare.com before you order.
The Oral Wegovy Pill: The Exception
The Wegovy pill (semaglutide tablets, taken once a day) is sold through NovoCare at its own self-pay prices, by dose: $149 a month for 1.5 mg, $199 for 4 mg and $299 for 9 mg and 25 mg, where one month is a bottle of 30 tablets (NovoCare (novocare.com), checked 26 October 2026). Rybelsus, the oral semaglutide tablet for type 2 diabetes, is a different product.
This matters because the lower pill doses cost less than any pen fill after the starter offer: $149 against $349. The pill has to be taken daily, and dosing and side effects differ from the weekly injection, so the choice is one to make with your clinician, not on price alone.
Who might benefit most from switching to oral Wegovy at current pricing:
- Patients who have already completed the starter-dose titration phase and are managing well
- Patients with needle aversion who have been hesitant about injectables
- Patients focused on long-term cost management past the first six months
Ask your prescribing clinician whether oral semaglutide is clinically appropriate for your situation before switching.
For Insured Patients: The List Price Cut Changes Your Copay Math
Separate from NovoCare, press reports in September 2026 said Novo Nordisk plans to cut Wegovy's list price (the wholesale acquisition cost that insurers and pharmacy benefit managers negotiate from) from January 1, 2027. Novo Nordisk's own pages that we checked do not publish a list price, so we don't quote a figure here.
What this means for insured patients:
Insurance copays and coinsurance are calculated as a percentage of the negotiated price, which is derived from the list price. When the list price drops, insurance plans that apply cost-sharing before patient assistance or rebates pass through some savings. This does not mean you will automatically pay less, it depends on your plan's benefit structure, but it applies a downward pressure on the tier copays insurers set for 2027.
Who benefits most from the list price cut:
- Patients in high-deductible health plans where they pay a percentage of negotiated cost before deductible is met
- Patients whose insurance covers Wegovy under a coinsurance structure rather than a fixed copay
- Patients in states where state insurance mandates require coverage of FDA-approved weight-loss treatments
Who sees limited benefit:
- Patients in plans with strict formulary exclusions for GLP-1 weight-loss indications. The exclusion, not the price, is the barrier
- Patients using NovoCare (the list price change affects insured pricing, not the NovoCare direct program)
The list price change is largely irrelevant to the self-pay population who use NovoCare. For that population, only the NovoCare program prices matter.
Brand vs. Compounded: How the 2027 Math Changes
Compounded semaglutide from licensed 503A telehealth pharmacies has been the dominant choice for cost-conscious patients since 2024, and for clear reasons: brand injectable Wegovy at retail pharmacy prices was not a close comparison with compounded semaglutide at $99–$199/month from licensed clinics for most self-pay patients.
⚠️ Important disclosure: compounded semaglutide is not FDA-approved as a drug product. It is compounded from FDA-approved active pharmaceutical ingredients under 503A pharmacy rules, but the final product has not gone through the FDA's drug approval process.
The updated comparison for December 2026 and beyond:
Under NovoCare's current pricing, the new-patient price ($199/month) is competitive with compounded alternatives in months one and two. After that, at $349/month, the brand pen through NovoCare is still more expensive than most compounded options, but far less so than at retail pharmacy prices.
For patients who want FDA-approved injectable Wegovy and can absorb a higher monthly cost in exchange for brand-name assurance, the NovoCare program remains the most accessible path. For patients prioritizing cost, compounded semaglutide from a licensed telehealth clinic remains the lower-cost option, with the trade-off that it is a compounded product rather than an FDA-approved finished drug.
Where the gap narrows:
The Wegovy pill at $149/month for 1.5 mg ($299 at the highest doses) is competitive with the higher-tier compounded programs while those prices hold. If your situation is well-suited to oral dosing, that comparison is worth working through with your clinician.
For a deeper breakdown of what drives the compounded vs. brand choice beyond price, see Compounded vs. Brand Semaglutide: Cost, Legality & What to Pick.
Action Steps Before December 31, 2026
If the NovoCare pricing change will affect your costs, you have a decision window before December 31. Here is a practical checklist:
If you are NOT yet on GLP-1 therapy and considering injectable Wegovy:
- Review whether you qualify for the Medicare Bridge Program first ($50/month if on Part D). See Medicare GLP-1 Coverage 2026
- If not on Medicare, confirm your insurance status for Wegovy by calling your insurer's pharmacy benefit line
- If paying cash, decide whether the $199/month new-patient window (two fills, through December 31, 2026) matters to you
- Compare the NovoCare injectable path to the oral Wegovy option and to compounded alternatives from licensed clinics
- If starting now, confirm with your prescribing clinic that they can initiate your prescription before December 31
If you are already on injectable Wegovy via NovoCare at a maintenance dose:
- Check your dose's price at novocare.com
- Ask your prescribing clinician whether oral semaglutide is an appropriate alternative
- Compare compounded options. A licensed telehealth clinic with a current prescription on file may be able to transfer your care
If you are already on compounded semaglutide:
- No action needed for NovoCare pricing changes. Those do not affect compounded programs
- If your compounding pharmacy has been mentioning supply concerns, review our Compounded Semaglutide Fall 2026 supply guide
Frequently Asked Questions
Does the wegovy price 2027 change affect existing patients immediately on December 31?
No. NovoCare's terms say the $199 price applies only to a new patient's first two fills of the starter doses. Patients past those fills already pay $349 a month ($399 for Wegovy HD), so December 31 doesn't change their price. Confirm with NovoCare directly.
Is the oral Wegovy pill actually equivalent to injectable Wegovy?
No. The Wegovy pill (oral semaglutide) is taken once a day, while the Wegovy pen is injected once a week, and the drug is absorbed differently by each route, so the doses are not interchangeable. Both are FDA-approved for weight management. Individual response varies, so discuss with your clinician whether the oral route is appropriate for your specific case.
If I start on NovoCare today, will my starter price be locked in for the first two fills?
Yes, if you are new to the Wegovy Savings offer or NovoCare Pharmacy and fill before the offer ends: NovoCare lists $199 a month for two fills of 0.25 mg and 0.5 mg through December 31, 2026. NovoCare program terms are set by Novo Nordisk and can be modified. Confirm the current rate structure at novocare.com or with your pharmacy before starting.
Can I use GoodRx or manufacturer coupons on top of NovoCare?
NovoCare is a direct-purchase program, not a coupon or discount card. It cannot be stacked with other coupons or discount cards. Medicare beneficiaries cannot use manufacturer savings programs. Check with your pharmacy for the exact payment mechanics.
How does a list price cut affect what I pay at a regular pharmacy without NovoCare?
Your out-of-pocket cost at a standard retail pharmacy without insurance or NovoCare depends on the pharmacy's cash price, which is set from the list price. If the list price falls, pharmacies may lower their cash price, but there is no guarantee of a 1:1 pass-through. For a self-pay patient, NovoCare's own prices ($349 for the pen, $149 to $299 for the pill) are the figures to compare against.
Related Reading
- How Much Does GLP-1 Weight Loss Cost in 2026?
- Compounded vs. Brand Semaglutide: Cost, Legality & What to Pick
- Medicare GLP-1 coverage in 2026
- Medicare GLP-1 Bridge Program: How It Works
- Compounded Semaglutide Fall 2026: Is Supply Still Safe?
Compounded semaglutide and tirzepatide are not FDA-approved drug products. They are prepared by licensed 503A compounding pharmacies and are not substitutes for FDA-approved medications. Consult a licensed clinician before starting any GLP-1 therapy. This article does not constitute medical advice.
NovoCare program terms are set by Novo Nordisk and subject to change without notice. Prices in this article were read on novocare.com on 26 October 2026 and should be verified there before making financial decisions.
